ReferenceRRK6521

A Phase 2 Randomized Placebo-Controlled Study of Safety and Efficacy Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Research Summary

Research Overview
PI Name Dawson - C
Speciality
Sponsor Regeneron Pharmaceuticals Inc
Project Status Open
Proposed End Date 31/01/2021
Study Run through CRF? No
Target number of patients agreed to recruit 1
Recruitment so far 0